About the Editors

Manuchair Ebadi earned a B.S. degree in chemistry from Park University (Parkville, Missouri, 1960), an M.S. degree in pharmacology from the University of Missouri College of Pharmacy (Kansas City, 1962), and a Ph.D. degree in pharmacology from the University of Missouri College of Medicine (Columbia, 1967). He completed his postdoctoral training in the Laboratory of Preclinical Pharmacology at the National Institute of Mental Health (Washington, D.C., 1970), under the able direction of Erminio Costa, M.D., an eminent member of the National Academy of Sciences.

Dr. Ebadi served as Chairman of the Department of Pharmacology at the University of Nebraska College of Medicine from 1970 until 1988, and subsequently as Professor of Pharmacology, Neurology, and Psychiatry from 1988 through 1999. In July 1999, he was appointed Professor and Chairman of the Department of Pharmacology and Toxicology at the University of North Dakota School of Medicine and Health Sciences. In September 1999, Dr. Ebadi became Professor and Chairman of the newly created Department of Pharmacology, Physiology, and Therapeutics; in November 1999, he became Professor of Neuroscience; and in December 1999, he was appointed Associate Dean for Research and Program Development. In September 2000, Dr. Ebadi was appointed Director of the Center of Excellence in Neurosciences at the University of North Dakota School of Medicine and Health Sciences, and in March 2002, Associate Vice President for Medical Research at the University of North Dakota.

During his academic career, Professor Ebadi has received 36 awards, including the Burlington Northern Faculty Achievement Award (1987), the University of Nebraska's system-wide Outstanding Teaching and Creative Activity Award (1995); and was inducted into the Golden Apple Hall of Fame (1995) for having received 11 Golden Apple awards. He is a member of 18 research and scholarly societies including Alpha Omega Alpha Honor Medical Society.

In 1976, Dr. Ebadi became the Mid-America State Universities Association (MASUA) honor lecturer; in

1987, he received an award for Meritorious Contributions to Pharmaceutical Sciences from the University of Missouri Alumni Association; in 1995, he was honored by a Resolution and Commendation of the Board of Regents of the University of Nebraska for having developed a sustained record of excellence in teaching, including creative instructional methodology; and in 1996, he received the Distinguished Alumni Award from Park University, his alma mater. In November 2002, Dr. Ebadi received a Recognition Award in appreciation of his outstanding contribution to the UND School of Medicine. In May 2003, Dr. Ebadi received the Outstanding Block Instructor Award for outstanding performance "in the encouragement, enrichment, and education of tomorrow's physicians." In 2003, Dr. Ebadi was elected to the Prestigious Cosmos Club (Washington, D.C.) for individuals who have distinguished themselves in art, literature, or science.

Professor Ebadi discovered and characterized brain metallothioneins isoforms in 1983 and subsequently showed that they are able to scavenge free radicals implicated in Parkinson's disease. In addition, he showed that metallothionein averts a-synuclein nitration, enhances the elaboration of coenzyme Q10, increases the activity of complex I, enhances the synthesis of ATP, and as an antioxidant is fifty times more potent than glutathione. His research programs have been supported in the past and currently by the National Institute on Aging (AG 1705906); the National Institute of Environmental Health Sciences (NIEHS 03949); the National Institute of Child Health and Human Development (NICHD 00370); the National Institute of Neurological Disorders and Stroke (NINDS 08932, NINDS 34566, and NINDS 40160); and the Office of National Drug Control Policy, Counter Drug Technology Assessments Center (DATM 05-02-C-1252).

Professor Ebadi has written seven textbooks. The Pharmacology text was translated into Japanese in 1987 (Medical Science International LTD, Tokyo); the Core Concepts in Pharmacology was translated into Chinese in 2002 (Ho-Chi Book Publishing of Taiwan); and the Pharmacodynamic Basis of Herbal Medicine (CRC Press 2002) became a best seller.

On February 26, 2004, Dr. Ebadi received the University of North Dakota Foundation's Thomas J. Clifford Faculty Achievement Award for Excellence in Research and, on September 7, 2004, he received from President Charles E. Kupchella, the designation of Chester Fritz Distinguished Professor of Pharmacology, the highest honor bestowed by the University of North Dakota.

Ronald Frederick Pfeiffer earned a B.S. degree from the University of Nebraska (Lincoln, 1969), gradin uating with honors and becoming a member of Phi Beta Kappa. He completed his M.D. degree at the University of Nebraska College of Medicine (Omaha, A ^^M 1973). Dr. Pfeiffer JD| completed his intern-s|1jp jn internal medicine (1974) and residency in neurology (1977) at Walter Reed Army Medical Center in Washington, D.C.

Dr. Pfeiffer completed a student research fellowship in the Laboratory of Preclinical Pharmacology (1972) under the able direction of Erminio Costa, an eminent member of the National Academy of Sciences. From 1975 to 1977, during his neurology residency, he was a guest fellow at the Experimental Therapeutics Branch, NINDS, participating in research programs under the tutelage of D. B. Calne, D.M. In 2001, Professor Pfeiffer received an honorary Doctor of Laws degree from Concordia University in Nebraska.

Dr. Pfeiffer served as Professor and Chief of the Section of Neurology (1987-1993) at the University of Nebraska College of Medicine. Thereafter, he was appointed Professor of Neurology (1994-present) and then Vice Chairman of the Department of Neurology (1996-present) at the University of Tennessee College of Medicine.

Professor Pfeiffer is board certified in psychiatry and neurology (1979-present) and is a member of various medical and scientific societies, including the American Neurological Association. He has participated in numerous clinical trials of experimental agents for the treatment of PD and has written and lectured extensively about nonmotor aspects of PD, especially GI dysfunction.

+1 0

Post a comment